Molecular Targets COBRE

描述(由申请人提供)：路易斯维尔大学分子靶标生物医学研究卓越中心(MT-Cobre)专注于识别癌症治疗的新分子靶标，强调开发新疗法的结构生物学方法。MT-Cobre的总体目标是招募并确保作为UofL布朗癌症中心分子靶标计划成员的初级调查人员的成功。在最初的五年筹资期间，我们在实现最初申请的目标方面取得了相当大的进展。最初的五名科布雷科学家中有四名已经获得了NIH R01的资助，第五名被鼓励寻求其他方向。五名杰出的新科学家已经取代了他们的位置，其中三人的NIH R01申请正在审查中或正在修改以重新提交。在最初的资助期间，我们非常幸运地保留了MT-Cobre的所有教职员工。我们利用MT-Cobre的支持创建了一套有效的核心设施，大大提高了MT-Cobre研究人员和其他布朗癌症中心科学家的工作效率。续签申请增加了一个新的核心，即生物物理学核心设施，并删除了一个未得到充分利用的核心，即蛋白质组学核心设施。该提案的具体目标是：1.为每一位主要调查人员发展成功的独立研究事业，这将导致独立的R01赠款。2.发展核心设施，以加强主要调查人员和MT方案其他成员的研究能力。3.继续将分子目标方案发展为一项凝聚力很强的研究方案，以加强合作研究项目和资助机会。4.制定一个国家和国际认可的计划，吸引最优秀的研究生、博士后研究员和更多的教员。5.取得新的发现，为癌症患者提供更有效的治疗方法。在下一个资助期间，MT-Cobre将利用有针对性的招聘来扩大该计划的范围。为续签申请提供资金对于使该计划发挥其潜力至关重要。基于其目前的师资队伍和下一个资助期的预期增长，该项目有望成为全国首屈一指的抗癌药物开发项目之一。

DESCRIPTION (provided by applicant): The University of Louisville Molecular Targets Center of Biomedical Research Excellence (MT-COBRE) is focused on identification of novel molecular targets for cancer therapy, emphasizing structural biologic approaches for development of novel therapeutics. The overall objective of the MT-COBRE is to recruit and ensure the success of junior investigators who are members of the Molecular Targets Program at the UofL's Brown Cancer Center. We have made considerable progress towards accomplishment of the goals of the original application during the first five year funding period. Four of the original five COBRE scientists have received NIH R01 funding, the fifth was encouraged to pursue other directions. Five outstanding new scientists have taken their places, three of whom have NIH R01 applications under review or being revised for resubmission. We have been quite fortunate, during the initial funding period, to have retained all of the MT-COBRE faculty. We have leveraged the MT-COBRE support to create a set of effective Core Facilities which have significantly enhanced the productivity of the MT-COBRE investigators and other Brown Cancer Center scientists. The renewal application has added a new Core, the Biophysics Core Facility, and deleted a Core which was underutilized, the Proteomics Core Facility. The specific aims of the proposal are to: 1. develop successful independent research careers for each of the principal investigators that will lead to independent R01 grants. 2. develop core facilities that will enhance the research capability of the principal investigators and the other members of the MT program. 3. continue to develop the Molecular Targets Program as a cohesive research program which will enhance collaborative research projects and funding opportunities. 4. develop a nationally and internationally recognized program which will attract the very best graduate students, postdoctoral fellows and additional faculty. 5. make discoveries leading to new and more effective treatments for patients with cancer. During the next funding period, the MT-COBRE will utilize focused recruitment to enhance the scope of the program. Funding of this renewal application is critically important to allow the program to achieve its potential. Based on its current faculty and projected growth during the next funding period, this program is poised to become one of the nation's premiere cancer drug development programs.